Phreesia (NYSE:PHR) Rating Lowered to Hold at Wall Street Zen

Key Points

• Wall Street Zen downgraded Phreesia from "buy" to "hold" and several brokers have cut price targets, though the consensus across analysts remains a "Moderate Buy" with an average target of $22.
• Q1 earnings missed expectations — the company reported $0.02 EPS versus $0.07 expected and, despite 15.9% revenue growth, weaker guidance triggered a sell‑off that pushed the stock to a one‑year low (shares around $8.35 vs a 1‑year high of $32.76).
• Elevated risk and mixed investor activity: insiders sold roughly 70,358 shares in the last three months and a class‑action/fraud investigation was filed, while some institutional buyers (notably Pale Fire Capital) added about $10.4 million of stock.

Phreesia (NYSE:PHR - Get Free Report) was downgraded by analysts at Wall Street Zen from a "buy" rating to a "hold" rating in a note issued to investors on Saturday.

Several other equities analysts also recently issued reports on the stock. Barclays dropped their price target on shares of Phreesia from $26.00 to $24.00 and set an "overweight" rating for the company in a research note on Tuesday, December 16th. Mizuho reduced their price objective on shares of Phreesia from $22.00 to $19.00 and set an "outperform" rating on the stock in a research note on Tuesday, March 24th. BMO Capital Markets decreased their price objective on Phreesia from $32.00 to $14.00 and set an "outperform" rating for the company in a report on Tuesday. Truist Financial reaffirmed a "hold" rating and set a $11.00 target price (down from $24.00) on shares of Phreesia in a research report on Tuesday. Finally, Citigroup reaffirmed a "neutral" rating and set a $10.00 target price (down from $25.00) on shares of Phreesia in a report on Tuesday. Twelve analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Phreesia presently has an average rating of "Moderate Buy" and an average target price of $22.00.

Phreesia Stock Performance

Phreesia stock opened at $8.35 on Friday. The business has a 50 day moving average of $11.92 and a 200-day moving average of $17.34. Phreesia has a 1 year low of $7.77 and a 1 year high of $32.76. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.53 and a quick ratio of 2.44. The company has a market capitalization of $507.10 million, a P/E ratio of 278.20 and a beta of 0.86.

Phreesia (NYSE:PHR - Get Free Report) last posted its earnings results on Monday, March 30th. The company reported $0.02 EPS for the quarter, missing the consensus estimate of $0.07 by ($0.05). Phreesia had a return on equity of 3.23% and a net margin of 0.48%.The business had revenue of $127.07 million for the quarter, compared to analyst estimates of $126.75 million. During the same quarter in the prior year, the business earned ($0.11) earnings per share. The firm's quarterly revenue was up 15.9% on a year-over-year basis. On average, equities research analysts predict that Phreesia will post -1.1 earnings per share for the current year.

Insider Activity

In other Phreesia news, CFO Balaji Gandhi sold 8,009 shares of the stock in a transaction dated Thursday, January 8th. The stock was sold at an average price of $17.01, for a total transaction of $136,233.09. Following the completion of the sale, the chief financial officer directly owned 156,231 shares in the company, valued at approximately $2,657,489.31. This trade represents a 4.88% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, General Counsel Allison C. Hoffman sold 6,585 shares of Phreesia stock in a transaction dated Thursday, January 8th. The stock was sold at an average price of $17.01, for a total value of $112,010.85. Following the completion of the transaction, the general counsel directly owned 174,762 shares of the company's stock, valued at approximately $2,972,701.62. This trade represents a 3.63% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 70,358 shares of company stock worth $1,123,569 in the last three months. Corporate insiders own 5.50% of the company's stock.

Institutional Investors Weigh In On Phreesia

Large investors have recently added to or reduced their stakes in the business. Federated Hermes Inc. acquired a new position in Phreesia in the third quarter valued at approximately $32,000. Van ECK Associates Corp grew its position in shares of Phreesia by 78.7% during the 4th quarter. Van ECK Associates Corp now owns 2,502 shares of the company's stock worth $42,000 after buying an additional 1,102 shares during the period. Asset Management One Co. Ltd. acquired a new stake in shares of Phreesia during the 3rd quarter worth approximately $45,000. Rockefeller Capital Management L.P. increased its stake in shares of Phreesia by 354.6% in the 4th quarter. Rockefeller Capital Management L.P. now owns 2,755 shares of the company's stock valued at $47,000 after acquiring an additional 2,149 shares in the last quarter. Finally, KBC Group NV lifted its position in shares of Phreesia by 83.4% during the 4th quarter. KBC Group NV now owns 3,449 shares of the company's stock valued at $58,000 after acquiring an additional 1,568 shares during the period. Institutional investors and hedge funds own 92.10% of the company's stock.

Key Phreesia News

Here are the key news stories impacting Phreesia this week:

• Positive Sentiment: Pale Fire Capital bought about $10.4 million of PHR shares, signaling institutional conviction and providing buying support. Pale fire capital buys Phreesia (PHR) shares worth $10.4 million
• Neutral Sentiment: Analysis piece argues Phreesia may have hit a near-term bottom and is positioned to regain growth, but timing and visibility remain uncertain — a constructive long-term view that doesn’t remove near-term risk. Phreesia Hits Bottom in Q1: Rebound Ahead, Timing Uncertain
• Neutral Sentiment: Several firms (Robert W. Baird, JPMorgan, Citigroup) issued neutral ratings, suggesting cautious investor expectations rather than outright sell recommendations. Phreesia NYSE: PHR Earns "Neutral" Rating from Robert W. Baird Phreesia NYSE: PHR Earns "Neutral" Rating from JPMorgan Chase & Co. Citigroup Reaffirms Neutral Rating for Phreesia NYSE: PHR
• Negative Sentiment: Phreesia shares plunged after reporting its first full-year profit but issuing lower-than-expected 2027 revenue guidance; the market punished the weaker outlook despite the profit. Phreesia (PHR) Is Down 25.5% After First Full-Year Profit But Lower 2027 Revenue Guidance
• Negative Sentiment: A class-action / fraud investigation filing (Schall Law Firm) was announced, raising legal and reputational risk that can weigh on the stock. PHR Investors Have Opportunity to Join Phreesia, Inc. Fraud Investigation with the Schall Law Firm
• Negative Sentiment: Multiple brokers cut expectations and targets (Needham, Canaccord lowered target to $22, Stephens and BMO issued pessimistic forecasts), increasing downward pressure via weaker sell-side guidance. Needham & Company LLC Has Lowered Expectations for Phreesia NYSE: PHR Stock Price Canaccord Genuity Group Lowers Phreesia NYSE: PHR Price Target to $22.00 Stephens Issues Pessimistic Forecast for Phreesia NYSE: PHR Stock Price BMO Capital Markets Issues Pessimistic Forecast for Phreesia NYSE: PHR Stock Price
• Negative Sentiment: Following the earnings miss, PHR hit a new 1-year low, underscoring the immediate market reaction to weaker-than-expected results and guidance. Phreesia NYSE: PHR Reaches New 1-Year Low After Earnings Miss

About Phreesia

Phreesia, Inc NYSE: PHR is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company's cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.

Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.